Zachary Roberts - 01 Jul 2026 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Reporting relationship: President and CEO
Issuer ticker: ALLO
Reported as of: 01 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jul 2026, 17:51:21 UTC
Prior SEC filing: 04 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/Earl Douglas, Attorney-in-Fact

Key filing fact

Zachary Roberts filed Form 4 for Allogene Therapeutics, Inc. (ALLO) on 06 Jul 2026.

Key facts

This page summarizes Zachary Roberts's Form 4 filing for Allogene Therapeutics, Inc. (ALLO).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 06 Jul 2026, 17:51.

Change

Previous filing in this sequence was filed on 04 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001851044 Primary reporting owner

Roberts Zachary

Relationship: President and CEO
Address: 210 EAST GRAND AVE, SOUTH SAN FRANCISCO
Signature: /s/Earl Douglas, Attorney-in-Fact
Signature date: 06 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ALLO transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares: +134,530
Change %
Price: $0.000000^*
Shares after: 134,530
Date: 01 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 134,530
Exercise price
Footnotes: F1

ALLO transaction Derivative

Stock Option (Right to buy)

Award

Transaction value
Shares: +476,190
Change %
Price: $0.000000^*
Shares after: 476,190
Date: 01 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 476,190
Exercise price: $2.11
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from July 20, 2026, subject to continued service through the vesting date.

Footnote F2

25% of the shares subject to the stock option shall vest on July 1, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter.